Comparison of Two Techniques in Achieving Corneal Graft

October 7, 2016 updated by: University Hospital, Rouen

Comparison of Manual and Automated Techniques in Achieving Posterior Lamellar Transplantation of the Cornea

The cornea is a transparent membrane, half a millimeter thick, embedded as a window in front of the eye.

When the eye becomes opaque, the eye is not seeing and the only way to restore the visual acuity is to replace the cornea by performing a graft (4000 surgeries per year in France). In half the cases the opacification of the cornea is secondary to dysfunction of the endothelium, cell layer of 15 μm thickness, covering its posterior surface, in charge of regulating the moisture of the corneal thickness and therefore its transparency.

While the total corneal transplantation has long been the only intervention for these diseases, it is now possible, from 4-5 years, to replace only the very thin: it is called endothelial transplant or graft lamellar later. This intervention is now experiencing significant success as it reduces very significantly the incidence of complications found after transplantation of total cornea and the visual recovery period. This type of transplant is still difficult to achieve and the best technique is not yet established.

Indeed, posterior lamellar transplantation of the cornea may be done manually or using an automated device. Manual techniques allow the preparation of grafts extremely thin but are difficult to achieve while the automatic techniques, easier, prepare thicker grafts that may be less efficient in visual recovery.

The aim of this project is to conduct a prospective study in order to compare these two techniques in terms of postoperative visual recovery and the vitality of the graft during the first year. To date, there is no such study.

The department of Ophthalmology in the University Hospital of Rouen is one of the most famous French teams in the field of cornea transplants and receives many patients from different French regions. The recruitment of 40 patients needed to study should be done without great difficulty over a period of 18 months.

Study Overview

Status

Completed

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Rouen, France, 76031
        • UH Rouen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • men and woman
  • 18 years old or more
  • Patient having been informed about the study and having signed a non-opposition to the participation

Exclusion Criteria:

  • Patient presenting an associated eye pathology previously known and able to limit the visual recovery (age-related macular degeneration, diabetic retinopathy, ...)
  • Pregnant women, parturient or breast feeding
  • refusal to participate in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Manual preparation
Manual preparation of the graft
Standard Endothelial descemet membrane graft
ACTIVE_COMPARATOR: Automatized preparation
Automatized preparation of the graft with microkeratoma
Standard Endothelial descemet membrane graft

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Measurement of visual acuity
Time Frame: 1 year
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Occular hypertension
Time Frame: Day 7, Day 15, Month 1, Month 2, Month 6, 1 year
Measurement of occular hypertension
Day 7, Day 15, Month 1, Month 2, Month 6, 1 year
Measurement of visual acuity
Time Frame: Month 1, Month 2, Month 6
Month 1, Month 2, Month 6
Partial or complete graft detachment
Time Frame: Day 7, Day 15, Month 1, Month 2, Month 6, 1 year
% of detachment
Day 7, Day 15, Month 1, Month 2, Month 6, 1 year
Necessity of air injection
Time Frame: Day 7, Day 15, Month 1, Month 2, Month 6, 1 year
Necessity of air injection : yes/no
Day 7, Day 15, Month 1, Month 2, Month 6, 1 year
Defeat of the graft
Time Frame: Day 7, Day 15, Month 1, Month 2, Month 6, 1 year
Defeat of the graft : yes/no
Day 7, Day 15, Month 1, Month 2, Month 6, 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Marc MURAINE, Pr, UH Rouen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2012

Primary Completion (ACTUAL)

August 1, 2016

Study Completion (ACTUAL)

August 1, 2016

Study Registration Dates

First Submitted

April 25, 2012

First Submitted That Met QC Criteria

June 1, 2012

First Posted (ESTIMATE)

June 4, 2012

Study Record Updates

Last Update Posted (ESTIMATE)

October 10, 2016

Last Update Submitted That Met QC Criteria

October 7, 2016

Last Verified

October 1, 2016

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fuch's Endothelial Dystrophy

Clinical Trials on Endothelial descemet membrane graft

3
Subscribe